These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39596334)

  • 1. Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors.
    Salvia R; Rico LG; Morán T; Bradford JA; Ward MD; Drozdowskyj A; Climent-Martí J; Martínez-Cáceres EM; Rosell R; Petriz J
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer.
    Acheampong E; Allsopp RC; Page K; Wadsley MK; Beasley AB; Coombes RC; Shaw JA; Gray ES
    Clin Chem; 2024 Jan; 70(1):234-249. PubMed ID: 38175603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Tanaka H; Makiguchi T; Tozuka T; Kawashima Y; Oba T; Tsugitomi R; Koyama J; Tambo Y; Ogusu S; Saiki M; Gyotoku H; Hasegawa T; Miyauchi E; Sonoda T; Saito R; Nakatomi K; Sakatani T; Kudo K; Tsuchiya-Kawano Y; Nishio M
    Eur J Cancer; 2024 Dec; 213():115117. PubMed ID: 39522333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of senescence cell signature in patients with non-small cell carcinoma and melanoma receiving PD-L1/PD-1 inhibitors.
    Koh YW; Han JH; Haam S; Lee HW
    Mech Ageing Dev; 2024 Dec; 222():111999. PubMed ID: 39427851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.
    Wang Y; Ju X; Hua R; Chen J; Dai X; Liu L; Wang G; Bai Y; Hu H; Li X
    Br J Cancer; 2024 Dec; 131(11):1833-1845. PubMed ID: 39455880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).
    Landre T; Chouaïd C; Sadaoui N; Bouharati D; Taleb C
    J Chemother; 2024 Dec; 36(8):675-681. PubMed ID: 38303601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
    Morikawa N; Naito T; Morita M; Sekikawa M; Doshita K; Yabe M; Kodama H; Miura K; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Takahashi T
    J Geriatr Oncol; 2024 Sep; 15(7):101832. PubMed ID: 38997933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC.
    Li H; Liu J; Zhang L; Xu Y; Wang X; Lan S; Cui P; Wang G; Cai S; Cheng Y
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39615893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China.
    Li H; Yuan Y; Xu Q; Liang G; Hu Z; Li X; Zhang W; Lei H
    Front Immunol; 2024; 15():1487078. PubMed ID: 39635526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
    Hastings K; Yu HA; Wei W; Sanchez-Vega F; DeVeaux M; Choi J; Rizvi H; Lisberg A; Truini A; Lydon CA; Liu Z; Henick BS; Wurtz A; Cai G; Plodkowski AJ; Long NM; Halpenny DF; Killam J; Oliva I; Schultz N; Riely GJ; Arcila ME; Ladanyi M; Zelterman D; Herbst RS; Goldberg SB; Awad MM; Garon EB; Gettinger S; Hellmann MD; Politi K
    Ann Oncol; 2019 Aug; 30(8):1311-1320. PubMed ID: 31086949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    Elkrief A; Montesion M; Sivakumar S; Hale C; Bowman AS; Begüm Bektaş A; Bradic M; Kang W; Chan E; Gogia P; Manova-Todorova K; Mata DA; Egger JV; Rizvi H; Socci ND; Kelly DW; Rosiek E; Meng F; Tam G; Fan N; Drilon A; Yu HA; Riely GJ; Rekhtman N; Quintanal Villalonga Á; Dogan S; Bhanot U; Gönen M; Loomis B; Hellmann MD; Schoenfeld AJ; Ladanyi M; Rudin CM; Vanderbilt CM
    J Clin Oncol; 2024 Oct; 42(28):3339-3349. PubMed ID: 39038258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus.
    Xu HZ; Chen FX; Li K; Zhang Q; Han N; Li TF; Xu YH; Chen Y; Chen X
    Drug Deliv Transl Res; 2025 Jan; 15(1):269-290. PubMed ID: 38597996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization.
    Cheng Y; Han X; Lai X; Wei X
    Phytomedicine; 2024 Dec; 135():156093. PubMed ID: 39531934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhu Y; She J; Sun R; Yan X; Huang X; Wang P; Li B; Sun X; Wang C; Jiang K
    Front Immunol; 2024; 15():1493773. PubMed ID: 39575263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.